Comparison of the Roche Cobas® 4800 HPV assay to Roche Amplicor for detection of high-risk human papillomavirus

被引：0

作者：

S. Phillips

A. M. Cornall

D. A. Machalek

S. M. Garland

D. Bateson

M. Garefalakis

S. N. Tabrizi

机构：

[1] The Royal Women’s Hospital,Regional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases

[2] The Royal Women’s Hospital,Department of Microbiology and Infectious Diseases

[3] Murdoch Childrens Research Institute,Department of Obstetrics and Gynaecology

[4] University of Melbourne,undefined

[5] Family Planning New South Wales,undefined

[6] Family Planning Western Australia,undefined

来源：

European Journal of Clinical Microbiology & Infectious Diseases | 2016年 / 35卷

关键词：

Family Planning Clinic; Discrepant Sample; Roche Linear Array; Cobas Testing; Attend Family Planning Clinic;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Roche Amplicor HPV (AMP) had previously been used for detection of high-risk human papillomavirus (HR-HPV) in epidemiological and clinical studies. As this assay is no longer available, we compared its performance using PreservCyt samples from women aged of 18–24 years attending for routine cervical cytology screening to Roche Cobas® 4800 (Cobas) to determine if subsequent studies could continue using the Cobas assay. Overall 507 samples were tested on Cobas and compared to previous AMP results, with discrepant samples tested on Roche Linear Array. Results: Overall, agreement between the Cobas and AMP for the presence of HR HPV types was very high (κ = 0.81) (95 % CI: 0.76 - 0.87) with percentage agreement of 91.57 %. Cobas is comparable to AMP for the detection of HR-HPV types in a community recruited cohort of healthy women.

引用

页码：1305 / 1307

页数：2

共 8 条

[1]

Tabrizi SN(2014)Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study Lancet Infect Dis 14 958-66

[2]

Phillips S(2015)Comparison of the Roche Cobas((R)) 4800 HPV assay to Digene Hybrid Capture 2, Roche Linear Array and Roche Amplicor for Detection of High-Risk Human Papillomavirus Genotypes in Women undergoing treatment for cervical dysplasia J Clin Virol 62 63-5

[3]

Nygard M(2014)Comparative effectiveness study on human papillomavirus detection methods used in the cervical cancer screening programme BMJ Open 4 2796-8

[4]

Tabrizi SN(2012)Comparison of PapType to Digene Hybrid Capture 2, Roche linear array, and Amplicor for detection of high-risk human papillomavirus genotypes in women with previous abnormal pap smears J Clin Microbiol 50 295-303

[5]

Stoler MH(2012)The interplay of age stratification and HPV testing on the predictive value of ASC-US cytology. Results from the ATHENA HPV study Am J Clin Pathol 137 127-34

[6]

Mackinnon A(2000)A spreadsheet for the calculation of comprehensive statistics for the assessment of diagnostic tests and inter-rater agreement Comput Biol Med 30 2130-7

[7]

Stevens MP(2007)Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results J Clin Microbiol 45 61-5

[8]

Gage JC(2012)Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests J Clin Microbiol 50 undefined-undefined

← 1 →